Introduction
Microchimerism is explained as the simultaneous presence of few foreign cells with different genetic origins of different individuals in a person. Transfer of these cells through blood transfusion, organ transplantation and particularly the mutual transfer of cells between the mother and fetus during pregnancy is possible. The initial appearance of fetal cells in the maternal blood occurs from 7-16 weeks up to 24 gestational weeks, where at the time of birth it increases and reaches the maximum value (1) . In the maternal body, fetal cells can be present for up to 27 years after delivery, and the mother's cells will remain over 49 years in the child's body (2) (3) (4) .
This article is an overview of the role of fetal cells microchimerism in maternal health and diseases, especially autoimmune and cancer. Most of the data have been collected from the available evidence found through search in PubMed, Scopus, Springer, Sciencedirect and some other databases with an emphasis on literature published in the period 2000 to 2015.
History of fetal microchimerism finding
For the first time, in the early 1970s fetal microchimerism was identified in the mother's peripheral blood and lymphocytes cultured as a natural event in pregnant women (5-7). The pathogenicity theory of these cells was first proposed by Nelson in 1996 . He noted that transfer of the fetal cells to the maternal body following pregnancy may lead to maternal immune response to these foreign cells and brings about some reactions like graft-versus-host disease and autoimmune reaction (8) . Based on the ability of these cells to differentiate into multiple cell lineages or very early stem cells progenitor, they have been
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Use your device to scan and read the article online known as pregnancy-associated progenitor cells (PAPC) (9) . The data retrieved from available research articles about these cells though 2000-2015, are outlined in Table 1 .
Fetal cells microchimerism detection methods
Identification and study of fetal cells microchimerism are based on searching male cells and Y chromosome sequences in the maternal circulation. This detection is possible with amplification of SRY gene (sex-determining region Y) on the Y chromosome by using PCR method. This method is sensitive to detecting even one male cell per million female cells while it does not yield phenotypic information (10) .
Special probes for chromosomes X and Y are used in another method named FISH method (fluorescent in situ hybridization). In this method, specific probes for chromosome X, (BAC probe pDMX1, locus DXZ1) bind to the digoxigenin and specific probes for chromosome Y (band region Yp11.1-q11.1, locus DYZ3) connect to Spectrum Orange fluorochrome (Vysis).
Immuno-FISH method (combining the two, FISH and immunohistochemistry methods) is another method which identifies these cells (11) . To make sure about the results obtained from such methods, real time-PCR method has been used (12) . In addition, fetal male and female offspring can be used for human leukocyte antigen (HLA) typing and identifying specific HLA in mother's polymorphisms (13) .
How fetal microchimerism can be transferred to maternal body?
Early during pregnancy, the maternal lung tissue is the first choice for the traffic and implantation of embryonic cells. These cells path from the uterine veins to maternal large lower venous and pulmonary capillary bed which is around the small site and is receptive to these cells in the maternal lung (14) (15) (16) . Interestingly, studies on the mice model have indicated that before the formation of the placenta, embryonic stem cells with the ability to differentiate into several cells, migrate to the maternal organs (17) . After these transfections, they are implanted in mother's stem cell niches such as bone marrow and can be present and survive in reservoirs for several years (9, (18) (19) (20) . Based on the result in mice model of chemical damage induction, following the tissue damage they migrate, differentiate and play an important role in the mother's body response to tissue repair (21, 22) .
Changes in the maternal immune system function during Pregnancy
Maternal immune tolerance to the fetus plays a decisive role in successful pregnancy outcome. Also, trophoblastic cells express fas ligand and eliminate maternal T cell clones that react with fetal antigens. With cytokines and indole amine 2, 3-dioxygenase secretion, they cause tryptophan metabolism in the mother's body and around the fetus. As good sex-steroid modulators and HLA-G, they inhibit natural-killer cells which are involved in cellular immunity, and modulate the maternal immune system during pregnancy (23) . In addition, induction of T-regulatory cells and inhibition of Th1 and activation of Th2 in the mother's body, cause immune tolerance in the maternal immune system cells toward the fetus or her/his cells body and sustains the fetus for a successful pregnancy (24) . In fact, the maternal immune system utilizes the following two mechanisms not to respond against these foreign cells. The first mechanism of immune tolerance has been described through maturation of these cells in the mother's thymus, where they encounter the mother's antigens (25) . Second, the maternal native antigens after entering the fetus's body can induce differentiation of embryonic cells to T-regulatory elements. Following the migration to the mother's body, these cells may be influenced by the maternal immune system (26) .
Fetal cells' microchimerism function in the maternal body -Autoimmune diseases
Review of the related studies showed that embryonic stem cells in the maternal body are a mixture of paternal and maternal genes and the paternal genes are present in the mother's body as allo-antigens; thus, antibodies tend to act against them (27). In several studies, the incidence of these antibodies in autoimmune diseases (28) (29) (30) , such as scleroderma (12) , Rheumatoid arthritis (31-33), Lupus (34-36), Sjogren's syndrome (37, 38) , Thyroiditis (39-43), Multiple and systemic sclerosis (44) have been investigated as compared to healthy individuals. Since most autoimmune diseases occur in reproductive age women, etiological hypothesis of embryonic microchimerism in these diseases has attracted much attention (45, 46) .
Results of extensive studies on the role of fetal microchimerism in autoimmune thyroid disorders demonstrated that manifestation of thyroid autoimmune diseases in pregnant patients is moderated and during pregnancy they remit, whereas the condition is worsened after delivery and child birth (47) . The hypothesis that fetal cells may contribute to the pathogenesis of maternal thyroid autoimmune disease was highlighted through finding many of such cells in the mother's thyroid gland in cases with Hashimoto's thyroiditis and Graves' disease as compared to healthy women (23, 48, 49) . Sometimes, the fetal immune precursor cells can be present in various organs and after proliferation, differentiation and activation, with production of cytokine and chemokine, they tend to play their part in the onset of autoimmune diseases and intensify the immune response (30, 50) .
Also, maternal allo-reactive T-cells do not inhibit them and autoimmune diseases can be induced through the presence of these cells in mother's body (51) . Evidence shows that maternal thyroid gland is an important organ for implantation of fetal cells and their constant presence for many years. The cells which are stranger to the maternal immune system may be activated and increase the incidence of numerous problems in the postpartum period, such as Graves' disease after delivery and absence of inhibitory fetal immune system (52) . However, data of some studies have not shown a significant difference between the incidence of fetal microchimerism in autoimmune patient and healthy individuals and the data appear to be mixed and controversial (53-60).
-Cancer
The fetal microchimeric cells which are located around or within the tumor and characterized by the endothelial cell marker (CD31) expression, can be present in the blood or lymph vessels and play an important role in angiogenesis and gloomy prognosis of tumors (61) . The role of fetal microchimerism in development of cancer was considered, according to reproduction ability which is similar to stem cells and manufactures diverse cells. Therefore, several studies about the relationship between such cells and nonautoimmune diseases such as hepatitis C (62), solid tumors (63), cervical cancer (64), breast cancer (65) (66) (67) , and the papillary thyroid carcinoma have been performed (68, 69) . Based on the Immuno-FISH analysis, most of these cells express the common leukocyte antigen (CD45). Therefore, their presence in the cervical area could change the maternal immune system and make the woman prone to infection and cancers (70).
-Tissue repair and protective role
Results of the related studies suggest that fetal microchimeric cells are not only like carcinogens, but can also be involved in the response to carcinogens; with ability to differentiate to mature cells, they can repair the damaged tissues (70) . Furthermore, studies on breast cancer patients and healthy subjects have shown that the circulation of these cells in patients is significantly lower than healthy individuals. This suggests that they could have a positive protective role and inhibit breast cancer in the mother's body (65, 71) .
The hypothesis of protective role for these cells in lung cancer has been tested (72) . In 2003, Whiteman et al suggested that the risk of epithelial ovarian cancer in older ages may be reduced (73) . Data from a case-control study on tumor tissues and peripheral blood using a very sensitive method to find even a single male cell in 106 mother's cells showed the abundance of these cells among the circulating mononuclear cells of the women with papillary thyroid cancer who had been in the last delivery of male infants, as compared to healthy women. Suggesting their possible protective role against the development of thyroid neoplasms (74) .
Characterizing fetal microchimerism
These cells may be found in normal and tumor thyroid tissues and express thyroglobulin or can stand in maternal thyroid gland and form the follicular cells (75). Male fetal cells which are found in cervical cancer have cytokeratin markers (CD45) and are able to differentiate into hematopoietic and epithelial cell lines. Meanwhile other fetal michrocimeric cells that lack these two markers in normal tissues can act as a precursor cell and differentiate into cell types (64) . In addition, CD45+ male cells which are negative for MHC-II antigens cannot play a role as antigen processing cells (APC), but function as natural-killer cells (NK cells) and start cytotoxicity reactions against cancer cells in mother's body; finally, they have a protective role in maternal thyroid cancer (76) .
Also the cells that are Tg +/MHCII-are able to take role in repairing damaged tissues. Based on these results, the lack of expression of MHC-II antigens causes targeting of RET/PTC oncogene and will specifically start tumor in thyroid follicular cells (68) . The male fetus cells with CD45 +/MHCIIphenotype in the maternal body as tumorassociated macrophages often have an important role in tumor progression (77) . Evaluation of the fetal cells in breast cancer has shown that these cells with epithelial and mesenchymal markers expression are involved in the tumor stroma formation (78, 79) .
Since these cells are capable of producing several cell lines such as mesenchymal cells (80), epithelial cells (81, 82) , skeletal muscle (83), cells 
Conclusion
An overview of the results and data obtained from related studies over recent 10-15 years demonstrates different roles for fetal microchimeric cell in the maternal body, including natural microchimerism (no biological role), utility (damaged tissue repair) and pathogenesis (causing autoimmune disease and cancer) (91) (92) (93) (94) (95) (96) (97) .
Several studies have indicated that the isolation of fetal stem cells from maternal blood and their proliferation can be used in transplantation (98, 99) . According to the available evidence, such cells can be obtained from the umbilical cord (100), amniotic fluid (101) and the placenta tissue (102) .
Many investigations on identifying the role of these fetal michrocimeric cells in the mother's body and their phenotypes and genotypes have recently been carried out. Their novel roles in the treatment and determining the prognosis of various diseases are yet to be further explained.
